Neal James R — SEC Form 4 filings
SEC reporting owner CIK 1600865. 14 Form 4 filings on record with FilingPulse; latest filed 2026-07-28.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-02-13 to 2026-07-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 789 shares, $2,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 32.
- Largest priced transaction: purchase of 789 shares @ $2.54 ($2,000) in Processa Pharmaceuticals, Inc., filed 2026-04-02.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | Director | 7 | 1 leg · 789 sh · $2,000 | — | 8 |
| Akari Therapeutics Plc (AKTX) | Director | 5 | — | — | 11 |
| PALISADE BIO, INC. (PALI) | Director | 1 | — | — | 8 |
| Peak Bio, Inc. (PKBO) | Director | 1 | — | — | 5 |
Form 4 filings — Neal James R
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-28 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 62,221 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Option exercise (M): 203 · Option exercise (M): 203 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Purchase (P): 789 @ $2.54 | EDGAR |
| 2026-03-16 | 4 | Akari Therapeutics Plc (AKTX) | Purchase (P): 2,473 (derivative) · Purchase (P): 2,473 (derivative) @ $0.40 · Purchase (P): 3,093 (derivative) · Purchase (P): 3,093 (derivative) @ $0.40 | EDGAR |
| 2025-10-03 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 100,000 (derivative) @ $0 · Grant/award (A): 300,000 (derivative) @ $0 | EDGAR |
| 2025-09-18 | 4/A | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 31,206 (derivative) @ $0 | EDGAR |
| 2025-07-28 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 175,299 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 4,464 @ $1.12 · Grant/award (A): 4,464 (derivative) @ $1.12 · Grant/award (A): 4,464 (derivative) @ $1.12 | EDGAR |
| 2025-01-10 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 8,000,000 @ $0.00 | EDGAR |
| 2024-12-26 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 2,000,000 @ $0.00 | EDGAR |
| 2024-11-18 | 4 | Peak Bio, Inc. (PKBO) | Conversion (C): 37,850 · Disposition to issuer (D): 37,850 · Conversion (C) · Disposition to issuer (D): 33,340 (derivative) · Disposition to issuer (D): 500,000 (derivative) @ $0 | EDGAR |
| 2024-09-18 | 4 | Processa Pharmaceuticals, Inc. (PCSA) | Grant/award (A): 31,206 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | PALISADE BIO, INC. (PALI) | Option exercise (M): 5,100 @ $0 · Option exercise (M): 5,820 @ $0 · Option exercise (M): 5,100 (derivative) @ $0 · Option exercise (M): 5,820 (derivative) @ $0 · Option exercise (M): 12,160 (derivative) @ $0 · Option exercise (M): 12,160 (derivative) @ $0 · +2 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1600865 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →